Krazati (Adagrasib)

Adagrasib binds covalently to the cysteine residue of the KRAS G12C mutant protein, locking it in an inactive GDP‑bound state. This blocks downstream MAPK signaling, halting cell proliferation and inducing tumor regression in cancers driven by the KRAS G12C mutation.

The prescribed dose of Krazati is determined by the treating oncologist based on individual patient factors, disease stage, and clinical guidelines. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for Adagrasib in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Krazati, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Krazati (adagrasib) is a covalent, irreversible KRAS G12C inhibitor, similar to other agents in its class but differs in pharmacokinetic profile, dosing schedule, and specific safety data. Comparative choice depends on clinical trial results, physician experience, and individual patient characteristics.

Krazati tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Krazati is taken orally as a tablet, usually with water. The exact timing relative to meals and any specific administration instructions are provided by the prescribing physician and should be followed precisely.

Serious risks include liver enzyme elevations, interstitial lung disease, and cardiac toxicity such as arrhythmias. Patients should be monitored regularly for signs of hepatic dysfunction, respiratory symptoms, and cardiac abnormalities, and report any concerning symptoms promptly.

Krazati is contraindicated in patients with known hypersensitivity to adagrasib or any tablet excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inducers or inhibitors without appropriate monitoring.